A large health question with little current local data
New Zealand lacks contemporary evidence on the prevalence, distribution and health-system cost of common gut disorders, according to a University of Otago review published in the New Zealand Medical Journal.
The review examined available evidence on disorders of gut-brain interaction, or DGBI. This group of chronic conditions includes irritable bowel syndrome and functional dyspepsia. They can cause abdominal pain, changes in bowel habits and indigestion, even when clinicians cannot identify an underlying structural or organic disease.
The researchers found only four New Zealand studies reporting the prevalence of these disorders. The newest was published in 2002. The studies were also geographically limited, covering Wellington and Dunedin rather than providing a national picture.
That leaves health planners, clinicians and patients working with evidence that is both old and incomplete. The gap is especially important because the conditions can be persistent and burdensome, while their symptoms may lead to repeated consultations, investigations and ongoing care.
Who is missing from the evidence
The review found no prevalence data for Māori or Pacific peoples. That means the existing record cannot show whether these communities experience disorders of gut-brain interaction at different rates, face different barriers to care, or use health services in different ways.
Dr. Simone Bayer of the University of Otago, who led the work with colleagues, said the absence of strong contemporary evidence makes it difficult to establish how many New Zealanders are affected. It also prevents a clear assessment of demand on the health system and whether access to care differs among population groups.
This is not a small technical limitation. Prevalence data are a foundation for planning services. Without it, decision-makers cannot reliably estimate the need for primary care, specialist services, dietary support, symptom management or research investment. They also have less ability to judge whether current care reaches the people who need it.
International figures suggest the scale could be substantial
The Otago team looked to comparable publicly funded health systems for context. Contemporary research from the United Kingdom and Australia found that about 37% of adults met the criteria for at least one disorder of gut-brain interaction.
Those international findings do not establish a New Zealand prevalence rate. Differences in population, study design and health-care use matter, and the review does not claim that overseas figures can substitute for direct national measurement. But the comparison indicates why the missing local data deserves attention.
Using United Kingdom estimates of direct health-care costs for irritable bowel syndrome as a conservative proxy, the researchers modeled a possible annual direct health-care cost of about NZ$1.6 billion if one-third of New Zealand adults have a disorder of gut-brain interaction. Bayer emphasized that this is a modeled estimate, not a measurement of current New Zealand costs.
That distinction is crucial. A model can help describe the possible stakes of an evidence gap, but it cannot determine the actual burden without current local research. The point is not that NZ$1.6 billion is a confirmed national bill; it is that policymakers do not yet have the data needed to calculate one confidently.
Why a modern national picture matters
Disorders of gut-brain interaction are often discussed through individual diagnoses such as IBS, but the review treats them as a broad and common group of chronic conditions. A national study could establish how often they occur using modern diagnostic criteria, identify variations between communities, and show how people move through the health system.
Better evidence could also clarify costs beyond direct treatment. The review’s modeled estimate addresses direct health-care spending through an overseas proxy. People with recurring symptoms may also experience disruption to work, education and daily life, but the supplied evidence does not provide a contemporary New Zealand calculation for those wider effects.
For now, the clearest finding is the absence of an adequate baseline. The most recent prevalence studies identified are more than two decades old, are confined to two cities, and do not include data for Māori or Pacific peoples. That is too narrow a base for understanding a condition group that international research indicates may affect a substantial share of adults.
From a blind spot to a research priority
The Otago review does not offer a new national prevalence estimate. Instead, it identifies the work needed to create one: contemporary, representative New Zealand research that measures prevalence, care access and costs across populations.
Such studies would give public-health officials a firmer basis for allocating resources and give clinicians a clearer sense of the scale of need. They could also reveal where people are being underserved, a question the existing literature cannot answer.
For patients, the value of better data is practical. Conditions without visible structural disease can still produce significant and ongoing symptoms. Measuring their prevalence and impact is a first step toward making sure that their place in the health system is understood rather than assumed.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com






